Compare Realty Income Corp (O) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs Sanofi SA — how do they compare? Realty Income Corp trades at $54.27 (market cap $51.26B), while Sanofi SA trades at $40.1 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Realty Income Corp is more actively traded (12,300,266 versus 2,995,646). Which is the better fit depends on your goals — on Pluang, investors hold Realty Income Corp for 127 Days and Sanofi SA for 94 Days on average.
| O | SNY | |
|---|---|---|
Market Cap | $51.26B | $95.18B |
Volume | 12,300,266 | 2,995,646 |
Sector | Real Estate | Health |
52-Week High | $67.56 | $52.34 |
52-Week Low | $53.35 | $39.51 |
Typical Hold Time | 127 Days | 94 Days |
Enterprise Value | $81.88B | $114.48B |
Dividend Yield | 6.01% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $53.35, down 1.66% amid bearish technical signals and recent earnings misses. The REIT maintains strong fundamentals with 92.56% gross margins and consistent dividend payments, though rising bond yields pressure valuations. Analyst consensus remains cautiously optimistic with a $64.80 price target despite three consecutive quarterly EPS misses.
The stock faces near-term headwinds from technical weakness and interest rate sensitivity, but long-term investors may find value in the 6%+ dividend yield and A-rated balance sheet. Key risks include persistent earnings underperformance and debt levels approaching 40% of assets, requiring careful monitoring of Q3 2026 results due November 2.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
